None listed
Conditions
Brief summary
Cerebral Palsy (CP) is the most common physical disability in childhood impacting 1 in 700 Australians. It is the 5th most costly condition at >AUD $5Billion p.a. CP is a disorder of movement and posture due to a static early brain lesion, however the musculoskeletal (MSK) sequelae are progressive. Major MSK complications are hip displacement, scoliosis and skeletal fragility, which lead to pain, disability and major orthopaedic surgery. Our Australian Cerebral Palsy Register has tracked the cause and severity of persons with CP. Our national Hip Surveillance Guidelines track progression of hip displacement which has shown a strong association with Gross Motor Function. Our Australasian Cerebral Palsy Clinical Trials network has implemented 3 international clinical practice guidelines on early detection, early intervention and efficacy of interventions to improve functional outcomes. Our team is well placed to develop a national program incorporating identification of hip displacement with scoliosis and fracture surveillance and to examine the inter-relationship between MSK complications. In a prospective cohort of n=500 children with cerebral palsy, our Australian CP MSK Health Network aims to: 1. Identify novel clinical outcome assessments and biomarkers of onset and progression of hip displacement, scoliosis deformity and osteoporosis/bone fragility to identify therapeutic targets and prevent progression; 2. Develop and integrate national hip, spine and fracture registries to develop practice guidelines that will lead to improved MSK health and wellbeing of children with CP; 3. Examine the inter-relationships between hip, spine and bone health on progression of MSK deformity to clarify the natural history of MSK complications and identify novel therapeutic targets; 4. Develop a fracture risk assessment and decision tool for children with CP to allow for accurate prognosis and timely intervention to reduce impact of skeletal fragility.
Interventions
Prospective cohort study (n=500, Gross Motor Function Classification System (GMFCS) III-V, aged 4-8 years) for 4 years longitudinal evaluation of hip, spine and skeletal fragility onset, progression, biomarkers and risk factors for outcomes at 8-12 years; Annual Pelvic x-ray, anterior-posterior (AP) spine x-ray, duel energy x-ray absorptiometry (DXA), peripheral quantitative computer tomography (pQCT)- Delivered by paediatric radiographer, nuclear medicine technician or clinical researcher accredited to perform DXA and pQCT. It is anticipated that these assessments will take a total of 2 hours to perform. Undertaken annually for 4 years of the study. Annual questionnaires completed by parents and participants: Child Health Utility instrument (CHU9D), CPCHILD - delivered by clinical researchers. It is anticipated that it will take up to 60 minutes to complete these questionnaires. Undertaken annually for 4 years of the study. Physical activity: ActiGraph GT3X+ for 7 consecutive days Annual. Delivered by exercise physiologists. This is not a physical activity intervention, but rather a measure of physical activity that the child undertakes spontaneously. Undertaken annually for 4 years of the study. Blood tests: Calcium, Magnesium, Phosphate, (CMP) 25 Hydroxy vitamin D (25OHD). Annual. Blood collected by paediatric phlebotomist. A numbing cream will be applied prior to the collection of blood. It is anticipated blood collection will take 5 minutes. Undertaken annually for 4 years of the study.
Sponsors
Eligibility
Inclusion criteria
Prospective Study: Children aged 4-8 years with Cerebral Palsy GMFCS III-V
Exclusion criteria
Unable or unwilling to undertake annual review for 4 years